申请人:JINGLUWEIDAI INFORMATION CONSULTING SERVICE (BEIJING) CO. LTD.
公开号:US10617679B2
公开(公告)日:2020-04-14
The present disclosure relates to a compound of Formula I or a non-toxic pharmaceutically acceptable salt or solvate thereof, wherein each R1, R2, R3, and R4 is independently selected from methyl (—CH3) and trideuteromethyl (—CD3), at least one of R1, R2, R3, and R4 is selected from trideuteromethyl (—CD3).
The compound is a deuterated derivative of L-tetrahydropalmatine, which not only markedly improves pharmacological effects, but also significantly reduces cardiac side effects, liver toxicity, and remarkably decreases individual differences.
本公开涉及一种式I化合物或其无毒药学上可接受的盐或溶液,其中每个R1、R2、R3和R4独立地选自甲基(-CH3)和三氘代甲基(-CD3),R1、R2、R3和R4中至少有一个选自三氘代甲基(-CD3)。
该化合物是 L-四氢巴马汀的氚代衍生物,不仅明显提高了药理作用,还显著降低了心脏副作用和肝脏毒性,并明显减少了个体差异。